Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI in Oncology

08-Sep-2008 - Ireland

Elan Corporation, plc and Biogen Idec announced the initiation of the first clinical trial of TYSABRI® (natalizumab) in oncology. The first dose of TYSABRI was administered in the trial. The objectives of this Phase I/II study are to evaluate the safety and potential anti-tumor activity of TYSABRI in patients with relapsed or refractory multiple myeloma. TYSABRI is a recombinant, humanized monoclonal antibody that targets the adhesion molecule VLA4 (also known as alpha-4 integrin) that is expressed on the surface of many types of immune cells. VLA4 is also found on the surface of multiple myeloma cells and may be involved in their survival.

This Phase I/II, open-label, two-arm study is designed to evaluate the safety and anti-tumor activity of TYSABRI in patients with relapsed or refractory multiple myeloma. In the Phase I portion of the trial, a standard dose-escalation design will be used to assess the safety and tolerability of TYSABRI in up to 12 patients. In the Phase II portion of the study, up to 30 patients will be randomized to the tolerated doses identified in Phase I of the study.

Treatment cycles will consist of intravenous infusions of TYSABRI once every 28 days for 6 months. After 6 months, if the patient has achieved a partial or a complete response, he or she may continue to receive TYSABRI once every 28 days until progression of disease occurs.

Other news from the department research and development

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?

Last viewed contents

New Phase II data show Novartis' ACZ885 gave better pain relief and flare prevention for patients with chronic gout

Renal reabsorption in living devices - 3D bioprinted, vascularized proximal tubules mimic the human kidney's reabsorption functions

Renal reabsorption in living devices - 3D bioprinted, vascularized proximal tubules mimic the human kidney's reabsorption functions

Brain cancer cells hide while drugs seek - Tumor cells temporarily lose mutation to evade drugs targeting mutation

Brain cancer cells hide while drugs seek - Tumor cells temporarily lose mutation to evade drugs targeting mutation

FORMAC strengthens management with appointment of CSO and COO

Experimental drug shows promise against brain, prostate cancers

Right under your nose: A more convenient way to diagnose Alzheimer's disease - Certain proteins in nasal discharge can indicate the onset and progression of Alzheimer's, providing an avenue for early detection

Right under your nose: A more convenient way to diagnose Alzheimer's disease - Certain proteins in nasal discharge can indicate the onset and progression of Alzheimer's, providing an avenue for early detection

A bright spot for microbiological diagnostics - Researchers develop molecular probes to detect pathogens in clinical samples

A bright spot for microbiological diagnostics - Researchers develop molecular probes to detect pathogens in clinical samples

New findings on the enzyme that breaks down PET plastic - Scientists increase efficiency: Start-up company in preparation

New findings on the enzyme that breaks down PET plastic - Scientists increase efficiency: Start-up company in preparation

"Growing end" of inflammation discovered - Stopping chronic inflammatory diseases

"Growing end" of inflammation discovered - Stopping chronic inflammatory diseases

Nanoscale ruler reveals organization of the cell membrane - Freiburg biologists measure distances and the arrangement of membrane molecules in nanometer range

Nanoscale ruler reveals organization of the cell membrane - Freiburg biologists measure distances and the arrangement of membrane molecules in nanometer range

How plants control their active ingredients epigenetically - A new study shows how the production of pharmaceutically relevant substances in nightshade plants works and is regulated epigenetically

How plants control their active ingredients epigenetically - A new study shows how the production of pharmaceutically relevant substances in nightshade plants works and is regulated epigenetically

Largest ever epigenetics project launched